Vaccines are among the greatest triumphs of modern medicine, preventing millions of deaths every year.
Yet, despite their proven efficacy, some life-saving vaccines remain underused — and the Human Papillomavirus (HPV) vaccine is one of them.
As awareness grows about the link between HPV and multiple cancers, especially cervical cancer, the importance of vaccination against HPV cannot be overstated.
Understanding HPV: The Virus Behind Multiple Cancers
Human Papillomavirus (HPV) is a group of more than 200 related viruses, transmitted primarily through sexual contact.
While most HPV infections are asymptomatic and resolve spontaneously, certain “high-risk” strains particularly HPV types 16 and 18 are notorious for causing precancerous lesions and malignancies.
Globally, HPV is responsible for:
– Nearly 100% of cervical cancers
– 90% of anal cancers
– 70% of oropharyngeal cancers
– 70–80% of vaginal and vulvar cancers
– Over 60% of penile cancers
In addition, “low-risk” HPV types (6 and 11) cause genital warts and recurrent respiratory papillomatosis, a chronic airway condition that can be distressing and difficult to manage.
The infection Is so common that most sexually active individuals both men and women will acquire HPV at some point in their lifetime.
Fortunately, vaccination offers a powerful tool to prevent these outcomes.
HPV and Cervical Cancer Burden in India
India carries one of the highest burdens of cervical cancer worldwide.
According to WHO estimates, India accounts for nearly one-fourth of the global cervical cancer deaths — a staggering statistic given that most of these deaths are preventable.
– Annual incidence: ~120,000 new cases
– Annual deaths: ~75,000 women
– Peak age group: 35–59 years
Major cause: Persistent infection with high-risk HPV strains
The tragedy lies in the fact that cervical cancer develops slowly — over 10 to 15 years — offering ample opportunity for prevention through vaccination and screening.
Yet, limited awareness, social stigma, and myths about HPV have slowed the adoption of preventive measures.
How HPV Vaccines Work
HPV vaccines are virus-like particle (VLP) vaccines — they contain no live virus and cannot cause infection.
Instead, they mimic the outer protein shell of HPV, stimulating a strong and lasting immune response.
The currently available vaccines include:
1. Cervarix (bivalent): protects against HPV types 16 and 18
2. Gardasil (quadrivalent): protects against HPV 6, 11, 16, and 18
3. Gardasil 9 (nonavalent): protects against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, 58)
4. Cervavac (India’s indigenous quadrivalent vaccine by Serum Institute of India) – launched in 2023, offering an affordable and effective local option
These vaccines work best when given before exposure to the virus, i.e., prior to the onset of sexual activity.
Hence, early adolescence — around 9 to 14 years — is the ideal window for vaccination.
Who Should Get the HPV Vaccine?
1. Adolescent Girls (9–14 years)
This is the primary target group recommended by WHO and the Indian government. A two
dose schedule (at 0 and 6–12 months) provides excellent protection.
2. Adolescent Boys (9–14 years)
Vaccinating boys not only protects them from HPV-related cancers and warts but also
reduces transmission, contributing to herd immunity.
3. Catch-up Vaccination (15–26 years)
Individuals up to 26 years who missed vaccination earlier can still benefit, though the
efficacy may be lower if HPV exposure has already occurred.
4. Adults (>26 years)
Vaccination in adults can be considered after risk–benefit discussion, especially for those
at ongoing risk of new sexual partners. However, routine vaccination is not recommended
beyond 26 years.
Why HPV Vaccination Matters — Beyond Cervical Cancer
While cervical cancer remains the most recognized outcome of HPV infection, the virus’s reach extends far wider.
In recent years, there has been a sharp increase in HPV-related throat and anal cancers — particularly among men.
Thus, vaccinating all genders serves both individual protection and public health goals.
The vaccine also reduces:
Genital warts, which can cause significant psychological distress.
Pre-cancerous lesions, thereby reducing the need for invasive treatments like biopsies, excisions, or hysterectomy.
Healthcare burden, by preventing cancers that require costly treatment and prolonged care.
In countries like Australia, which introduced HPV vaccination in 2007, cervical cancer is on track to be eliminated as a public health problem by 2035 — a testament to what widespread vaccination can achieve.
Safety, Efficacy, and Myths
Safety
HPV vaccines are extremely safe. Over 300 million doses have been administered globally, with an excellent safety record. Common side effects are mild — including injection-site pain, redness, and low-grade fever. Severe adverse events are exceedingly rare.
Efficacy
The vaccine is over 90% effective in preventing infection and precancerous lesions caused by the targeted HPV types. Protection lasts at least 10–15 years, and emerging data suggest even longer durability.
Common Myths
Myth: “HPV vaccine promotes early sexual activity.”
Fact: Multiple studies have shown no link between vaccination and changes in sexual behavior.
Myth: “It’s only for girls.”
Fact: HPV affects both men and women; vaccinating boys reduces cancer risk and community transmission.
Myth: “It causes infertility.”
Fact: No scientific evidence supports this claim. The vaccine protects reproductive health by preventing cancers that can require removal of reproductive organs.
Global and Indian Recommendations
World Health Organization (WHO)
HPV vaccination is part of WHO’s Cervical Cancer Elimination Strategy, which aims to ensure 90% of girls are vaccinated by age 15 by 2030.
It forms the “first pillar” of the 90–70–90 global targets (90% vaccination, 70% screening coverage, 90% treatment access).
Government of India
In 2023, the Union Health Ministry approved inclusion of the HPV vaccine in the Universal Immunization Programme (UIP) for girls aged 9–14 years.
The indigenous vaccine Cervavac makes large-scale immunization affordable and feasible.
Several states, including Delhi and Sikkim, have already started school-based HPV vaccination drives.
The Road Ahead: Awareness and Action
Despite strong scientific backing, uptake remains low in India. The reasons range from limited awareness and vaccine hesitancy to cultural taboos surrounding sexual health.
Healthcare professionals play a crucial role in bridging this gap.
Steps to Improve Coverage
1. School-based vaccination programmes — the most effective model globally.
2. Public education campaigns to dispel myths and normalize HPV vaccination as a cancer-prevention tool, not a “sex-related” vaccine.
3. Engaging healthcare providers — pediatricians, gynecologists, and family physicians — to recommend the vaccine proactively.
4. Media and influencer involvement to reach broader audiences, particularly in rural and semi-urban areas.
5. Collaboration between public and private sectors for sustained funding and logistics.
Conclusion: A Preventable Cancer Deserves No Victims
The story of HPV vaccination is one of immense promise.
With safe, effective, and affordable vaccines available, no woman should die of cervical cancer — and no man or woman should face an HPV-related malignancy that could have been prevented.
As India moves toward eliminating cervical cancer as a public health problem, HPV vaccination stands as a cornerstone of that vision.
It is not merely a medical intervention; it is an act of empowerment — protecting our daughters and sons, preserving families, and
safeguarding future generations.
The message Is simple and powerful:
– HPV vaccination is cancer prevention.
– Protect early, protect for life.